News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
256,145 Results
Type
Article (13718)
Company Profile (257)
Press Release (242170)
Section
Business (79141)
Career Advice (147)
Deals (13168)
Drug Delivery (28)
Drug Development (50132)
Employer Resources (31)
FDA (5631)
Job Trends (5107)
News (143559)
Policy (10012)
Tag
Academia (901)
Africa (145)
Allergies (30)
Alliances (21395)
Alzheimer's disease (680)
Antibody-drug conjugate (ADC) (31)
Approvals (5594)
Arizona (38)
Artificial intelligence (29)
Asia (16631)
Australia (2776)
Bankruptcy (96)
Best Places to Work (4343)
Biotechnology (215)
C2C Services and Suppliers (10611)
California (1167)
Canada (478)
Cancer (272)
Career advice (128)
CAR-T (33)
Cell therapy (93)
China (87)
Clinical research (38983)
Collaboration (81)
Colorado (34)
Compensation (37)
Connecticut (38)
COVID-19 (976)
Cystic fibrosis (58)
Data (198)
Diabetes (38)
Diagnostics (1154)
Earnings (28356)
Employer resources (29)
Europe (35648)
Events (45724)
Executive appointments (87)
FDA (5730)
Florida (116)
Funding (92)
Gene editing (27)
Gene therapy (77)
GLP-1 (259)
Government (1050)
Healthcare (6509)
Hotbed/Location (184141)
Illinois (70)
Indiana (42)
Infectious disease (985)
Inflammatory bowel disease (78)
IPO (7131)
Job creations (856)
Job search strategy (124)
Kansas (52)
Layoffs (177)
Legal (1368)
Lung cancer (64)
Maryland (177)
Massachusetts (955)
Medical device (2515)
Medtech (2516)
Mergers & acquisitions (6029)
Metabolic disorders (127)
Michigan (37)
Minnesota (65)
Neuroscience (780)
New Jersey (312)
New York (379)
NextGen Class of 2024 (1975)
Non-profit (838)
North Carolina (320)
Northern California (516)
Obesity (72)
Ohio (62)
Opinion (86)
Parkinson's disease (29)
Patents (34)
Peanut (27)
Pennsylvania (270)
People (24676)
Pharmaceutical (41)
Phase I (13680)
Phase II (18127)
Phase III (11533)
Pipeline (69)
Postmarket research (842)
Preclinical (5759)
Press Release (30)
Rare diseases (101)
Real estate (1407)
Regulatory (8006)
Research institute (928)
South America (206)
Southern California (484)
Startups (1962)
Texas (106)
United States (4492)
Vaccines (129)
Washington State (149)
Weight loss (56)
Date
Today (54)
Last 7 days (415)
Last 30 days (1198)
Last 365 days (21436)
2024 (14829)
2023 (22412)
2022 (26823)
2021 (27811)
2020 (23363)
2019 (16237)
2018 (11745)
2017 (13748)
2016 (11841)
2015 (14354)
2014 (10393)
2013 (7486)
2012 (7532)
2011 (7614)
2010 (7428)
256,145 Results for "peloton therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Deals
Peloton Interactive, Inc. Announces Proposed Public Offering of Class A Common Stock
Peloton Interactive, Inc. (“Peloton”) (Nasdaq: PTON) today announced that it has commenced an underwritten public offering of $1 billion of shares of its Class A common stock.
November 16, 2021
·
4 min read
Deals
Peloton Signs Agreement To Acquire Precor
Acquisition expected to establish Peloton’s U.S. manufacturing footprint, enhance R&D capabilities, and accelerate growth of commercial verticals
December 21, 2020
·
9 min read
Pharm Country
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
Aquestive Therapeutics, Inc. announced that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host investor meetings on July 9, 2024.
June 27, 2024
·
2 min read
Genetown
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
Inhibikase Therapeutics, Inc. today announced expansion of its therapeutic pipeline and multiple updates to its Research and Development programs.
June 5, 2024
·
6 min read
Business
Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases
Ascidian Therapeutics today announced a research collaboration and licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery and development of RNA exon editing therapeutics targeting neurological diseases.
June 18, 2024
·
3 min read
Pharm Country
VYNE Therapeutics to Participate in Leerink Partners Therapeutics ForumBoston event to focus on Immunology & Inflammation (I&I) and Metabolic Diseases
VYNE Therapeutics Inc. today announced members of VYNE’s management will participate in one-on-one meetings at the Leerink Partners Therapeutics Forum on Immunology and Inflammation and Metabolic Diseases on Tuesday, July 9, 2024.
June 26, 2024
·
1 min read
Pharm Country
Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.
Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced plans to accelerate its development initiatives in obesity and cardiometabolic disease through the acquisition of the assets of Better Therapeutics, Inc.
May 22, 2024
·
7 min read
Deals
Orna Therapeutics Announces Strategic Acquisition of ReNAgade Therapeutics to Solidify Leadership in Circular RNA Therapies
Orna Therapeutics today announced its acquisition of ReNAgade Therapeutics, a pioneer in unlocking the potential of RNA therapeutics that demonstrated industry-leading delivery to multiple extra-hepatic cells in non-human primate (NHP) models over the past 18 months.
May 23, 2024
·
4 min read
Deals
AbbVie Acquires Celsius Therapeutics
AbbVie (NYSE: ABBV) announced today the acquisition of Celsius Therapeutics, Inc. (“Celsius”), a privately held biotechnology company pioneering new therapies for patients with inflammatory disease.
June 27, 2024
·
4 min read
1 of 25,615
Next
